Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 8
  • 11
  • 4
  • 11

Found 11 Multiple Sclerosis trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (BEAT-MS)
18 - 55
All genders
The purpose of this study is to compare efficacy and safety of Autologous Hematopoietic Stem Cell Transplant (AHSCT) to best available therapy (BAT) in relapsing MS. Best available therapy is referring to the best available medications that are used to treat MS. Patients who agree to participate in the experimental …
99 or below
All genders
Phase 4
The primary study objective is to evaluate the rate of durable remission of relapsing disease activity, assessed serially both clinically and by MRI, from randomization through 48 months in participants with early relapsing multiple sclerosis who discontinue OCR after 12 and 24 months of treatment. Secondary objectives include: - Mechanistic: …
18 - 55
All genders
The overall objectives of this study are to evaluate feasibility and safety of thoracic duct sampling, including "in-and-out" cannulation and "indwelling" catheterization in early MS and to compare cellular and signaling markers in thoracic duct lymph compared to measures in the blood, within and across populations of MS patients before …
 A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ Technology in Adults with Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)
18 - 99
All genders
If you have type 2 diabetes and use short and long acting insulin then we would love to talk to you!   The study is being done to learn if an automated insulin delivery (AID) system can safely control blood sugar in people with type 2 diabetes. We will refer …
18 - 50
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …
 The International MS Microbiome Study
18 - 90
All genders
Dr. Amit Bar-Or, MD, FRCPC from the University of Pennsylvania Department of Neurology is conducting a study to investigate how the structure and activity of gastrointestinal microbes (bacteria and fungi) found in the gut contribute to multiple sclerosis pathogenesis. You are being asked to participate in this study because either …
99 or below
All genders
This study aims to investigate the benefits of collecting lymph in addition to blood in patients with multiple sclerosis (MS). It is now well recognized that the central nervous system (CNS) is not as immune privileged as it has been considered. A system of lymphatic drainage has been described both …
99 or below
All genders
This trial evaluates the effects of His or left bundle branch pacing (LBBP) comparative to biventricular pacing on quality of life, exercise capacity, hospitalization for heart failure, and mortality in patients with HF and conduction system disease. Study population is patients with heart failure with reduced ejection fraction (HFrEF) less …
 Healthy volunteers for Neuroinflammatory research study
18 - 60
Accepts healthy volunteer
All genders
We are conducting research studies on how immune system cells contribute to inflammatory conditions of the nervous system, such as multiple sclerosis, neuromyelitis optica (NMO), encephalitis, head injury, epilepsy, Parkinson's disease (PD), Alzheimer's disease (AzD), Lou Gherig's disease (amyotrophic lateral sclerosis; ALS) frontotemporal dementia (FTD) and others. This includes investigating …
99 or below
All genders
Phase 2
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
1 - 10 of 11